Circulating Tumor Cells (CTC) in Lung Cancer
The primary objective of this study is to establish circulating tumor cell (CTC) derived xenografts and assess the activity of novel DNA repair inhibitors as a function of DNA repair mutations detected in CTC samples (personalize DNA repair therapy).
Checked against the public recordLast updated Apr 24, 2026 · Source: ClinicalTrials.gov
What this study is about
- Purpose
- Not specified
- Study type
- Observational
- Phase
- Not applicable
- Sponsor
- Shadia Jalal
- Interventions being studied
- Other: Blood draw
How this study is categorized
These labels come from structured fields and exact terms in the public record.
Who may be able to participate
Inclusion Criteria Cohort A (one-time blood sample) \& Cohort B (multiple blood samples) * Histologically or cytologically confirmed lung cancer (both non-small cell lung cancer and small cell lung cancer are allowed) * Stage 4 NSCLC or extensive-stage SCLC * Newly diagnosed disease with no prior systemic therapy for advanced disease Note: Patients that have received prior adjuvant chemotherapy or prior chemoradiotherapy for earlier stage lung cancer are allowed if treatment was completed ≥3 months. * Age ≥ 18 years * Ability to understand and the willingness to sign a written informed consent document Inclusion of Women and Minorities Both men and women of all races and ethnic groups are eligible for this study.
Important: This is the sponsor’s public criteria, not a determination of eligibility. The study team must review your individual situation.
U.S. locations
- Indiana University Health Melvin and Bren Simon Cancer CenterIndianapolis, Indiana
- Roudebush VA Medical CenterIndianapolis, Indiana
Source and freshness
Processed from ClinicalTrials.gov. Last public update: Apr 24, 2026. Always confirm current availability with the study team.